Press release
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) and Vetophage, a company specialized in phage therapy applied to animal health, announce the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance.